Sichuan Baili Pharmaceutical
688506 · SSE STAR Market
Public Market Listing
Live quotes, historical charts, and market capitalization for Sichuan Baili Pharmaceutical are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(9 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | EGFR + HER3Multispecific antibody | Non-Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaEsophageal Cancer Esophageal Squamous Cell Carcinoma | |
| Phase 3 | EGFR + HER3Antibody–drug conjugate | Non-Small Cell Lung CancerBreast CancerOvarian CancerBiliary Tract CancerBladder / Urothelial CancerNasopharyngeal CarcinomaEsophageal Cancer HR+/HER2- Metastatic Breast Cancer, Urothelial Carcinoma, Esophageal Squamous Cell Carcinoma | |
| Phase 3 | HER2Antibody–drug conjugate | Non-Small Cell Lung CancerOvarian CancerColorectal CancerBiliary Tract CancerBreast CancerBladder / Urothelial Cancer HER2-Positive Breast Cancer, Urothelial Carcinoma | |
| Phase 2 | Undisclosed / early pipelineAntibody–drug conjugate | Non-Small Cell Lung Cancer | |
| Phase 2 | PD-1 x CTLA-4Multispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 1/2 | TROP2Antibody–drug conjugate | Non-Small Cell Lung Cancer | |
| Phase 1/2 | ROR1 (plus T-cell engaging costimulatory components)Multispecific antibody | Acute Myeloid LeukemiaChronic Lymphocytic Leukemia Relapsed/Refractory Chronic Lymphocytic Leukemia | |
| Phase 1 | Undisclosed / early pipelineAntibody–drug conjugate | Non-Small Cell Lung Cancer | |
| Phase 1 | CD3 x tumor antigen x immune checkpoint (multi-specific)Monoclonal antibody | Non-Small Cell Lung Cancer |
Upcoming events
(67 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (22)
November 2026 (2)
December 2026 (20)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (17)
January 2027 (1)
What to watch
May 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
June 2027 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
July 2027 (1)
What to watch
2028 (15)
March 2028 (1)
What to watch
December 2028 (14)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2029 (6)
January 2029 (1)
What to watch
December 2029 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
2030 (2)
2031 (3)
2032 (1)
December 2032 (1)
What to watch
2033 (1)
December 2033 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | — | $430M | — | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $351M | $350M | — | $147M | report ↗ |
Sichuan Baili Pharmaceutical reported revenue of $350.85M, down 56.7% YoY, R&D spend of $350M, up 74.3% YoY, and a quarterly net burn of $146.68M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text